Bangladesh pharma eyes UAE exports

19 January 2009

Pharmaceutical companies in Bangladesh are trying to boost its pharmaceutical exports to the United Arab Emirates and Middle East as  the country enjoys unique concessions as a least-developed country under  World Trade Organization drug patent rules, a senior government  official told the Emirates Business publication.

Bangladesh, one of the poorest South Asian countries and the 10th most  populous country in the world, is currently facing a critical economic  scenario due to the sharp decline in garment exports to the USA and  Europe.

Mohammed Shahjalal, Assistant Director, Export Promotion Bureau under  the Bangladesh Ministry of Commerce told the newspaper that the drug  industry is poised to be the latest growth sector due to the favorable  position as a least developed country. "We are trying to boost  pharmaceutical exports to the [Gulf Cooperation Council states] and  efforts are on to get registration from the UAE Ministry of Health. Many  pharmaceutical companies and multinationals have expanded their  production capacity in Bangladesh because, as a least-developed country,  we have until 2016 to produce cheap generic drugs," he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight